Correlation of knee strength to functional outcomes in becker muscular dystrophy

Muscle and Nerve

Volumn 47, Issue 4, 2013, Pages 550-554

  Alfano, Lindsay N ^a   Lowes, Linda P ^a   Flanigan, Kevin M ^a   Mendell, Jerry R ^a  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

Author keywords

Becker muscular dystrophy; Function; Knee extension; Knee flexion; Strength

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BECKER MUSCULAR DYSTROPHY; BERG BALANCE SCALE; CLIMBING; CLINICAL ARTICLE; CONTROLLED STUDY; EXTENSOR MUSCLE; FLEXOR MUSCLE; FUNCTIONAL ASSESSMENT; HUMAN; KNEE EXTENSOR MUSCLE; KNEE FUNCTION; LEG; MALE; MUSCLE STRENGTH; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PSYCHOMETRY; STAIR CLIMBING; TIMED WALKING TEST; WALKING;

ADOLESCENT; ADULT; AGED; EXERCISE TEST; HUMANS; KNEE JOINT; MALE; MIDDLE AGED; MUSCLE STRENGTH; MUSCLE WEAKNESS; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; OUTCOME ASSESSMENT (HEALTH CARE); QUADRICEPS MUSCLE; YOUNG ADULT;

EID: 84875614164     PISSN: 0148639X     EISSN: 10974598     Source Type: Journal    
DOI: 10.1002/mus.23660     Document Type: Article

References (26)

1. Magri F, Govoni A, D'Angelo MG, Del Bo R, Ghezzi S, Sandra G, et al. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol 2011;258:1610-1623.
2. Flanigan KM, Dunn DM, von Niederhausern A, Howard MT, Mendell JR, Connolly A, et al. DMD Trp3X nonsense mutation associated with a founder effect in North American families with mild Becker muscular dystrophy. Neuromuscul Disord 2009;19:743-748.
3. Kota J, Handy CR, Haidet AM, Montgomery CL, Eagle A, Rodino-Klapac LR, et al. Follistatin gene delivery enhances muscle growth and strength in nonhuman primates. Sci Transl Med 2009;1:6ra15.
4. Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR. Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 2009;39:283-296.
5. Mendell JR, Csimma C, McDonald CM, Escolar DM, Janis S, Porter JD, et al. Challenges in drug development for muscle disease: a stakeholders' meeting. Muscle Nerve 2007;35:8-16.
6. Brooke MH, Fenichel GM, Griggs RC, Mendell JR, Moxley RT, Miller JP, et al. The CIDD Group: Clinical investigation in Duchenne dystrophy: 2. Determination of the "power" of therapeutic trials based on the natural history. Muscle Nerve 1983;6:91-103.
7. Tawil R, McDermott MP, Mendell JR, Kissel J, Griggs RC, FSH-DY Group . Facioscapulohumeral muscular dystrophy (FSHD): design of natural history study and results of baseline testing. Neurology 1994;44:442-446.
8. Kissel JT, McDermott MP, Mendell JR, King WM, Pandya S, Griggs RC, et al. Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy. Neurology 2001;57:1434-1440.
9. Tawil R, McDermott MP, Pandya S, King W, Kissel J, Mendell JR, et al. A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. Neurology 1997;48:46-49.
10. Lowes LP, Alfano L, Viollet L, Rosales XQ, Sahenk Z, Kaspar BK, et al. Knee extensor strength exhibits potential to predict function in sporadic inclusion-body myositis. Muscle Nerve 2012;45:163-168.
11. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Atkinson L, et al. The 6-minute walk test in Duchenne/Becker muscular dystrophy: longitudinal observations. Muscle Nerve 2010;42:966-974.
12. Podsiadlo D, Richardson S. The timed "Up & Go": a test of basic functional mobility for frail elderly persons. J Am Geriatr Soc 1991;39:142-148.
13. Berg KO, Wood-Dauphinee SL, Williams JI, Maki B. Measuring balance in the elderly: validation of an instrument. Can J Public Health 1992;83(suppl 2):S7-11.
14. Cattaneo D, Jonsdottir J, Repetti S. Reliability of four scales on balance disorders in persons with multiple sclerosis. Disabil Rehabil 2007;29:1920-1925.
15. Blum L, Korner-Bitensky N. Usefulness of the Berg Balance Scale in stroke rehabilitation: a systematic review. Phys Ther 2008;88:559-566.
16. Landers MR, Backlund A, Davenport J, Fortune J, Schuerman S, Altenburger P. Postural instability in idiopathic Parkinson's disease: discriminating fallers from nonfallers based on standardized clinical measures. J Neurol Phys Ther 2008;32:56-61.
17. Bohannon RW, Williams Andrews A. Normal walking speed: a descriptive meta-analysis. Physiotherapy 2011;97:182-189.
18. Bohannon RW. Reference values for the timed up and go test: a descriptive meta-analysis. J Geriatr Phys Ther 2006;29:64-68.
19. Muir SW, Berg K, Chesworth B, Speechley M. Use of the Berg Balance Scale for predicting multiple falls in community-dwelling elderly people: a prospective study. Phys Ther 2008;88:449-459.
20. Mendell JR, Rodino-Klapac LR, Malik V. Molecular therapeutic strategies targeting Duchenne muscular dystrophy. J Child Neurol 2010;25:1145-1148.
21. Malik V, Rodino-Klapac LR, Mendell JR. Emerging drugs for Duchenne muscular dystrophy. Expert Opin Emerg Drugs 2012;17:261-277.
22. McDonald CM, Henricson EK, Han JJ, Abresch RT, Nicorici A, Elfring GL, et al. The 6-minute walk test as a new outcome measure in Duchenne muscular dystrophy. Muscle Nerve 2010;41:500-510.
23. Gibbons WJ, Fruchter N, Sloan S, Levy RD. Reference values for a multiple repetition 6-minute walk test in healthy adults older than 20 years. J Cardiopulm Rehabil 2001;21:87-93.
24. Janaudis-Ferreira T, Sundelin G, Wadell K. Comparison of the 6-minute walk distance test performed on a non-motorised treadmill and in a corridor in healthy elderly subjects. Physiotherapy 2010;96:234-239.
25. Niedeggen A, Skobel E, Haager P, Lepper W, Muhler E, Franke A. Comparison of the 6-minute walk test with established parameters for assessment of cardiopulmonary capacity in adults with complex congenital cardiac disease. Cardiol Young 2005;15:385-390.
26. Pohl PS, Duncan PW, Perera S, Liu W, Lai SM, Studenski S, et al. Influence of stroke-related impairments on performance in 6-minute walk test. J Rehabil Res Dev 2002;39:439-444.